Molecular and physiological effects of nesiritide

Canadian Journal of Cardiology

Volumn 24, Issue SUPPL. B, 2008, Pages 15B-18B

  Reichert, S ^a   Ignaszewski, Andy ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Acute decompensated heart failure; BNP; Nesiritide

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; GLYCERYL TRINITRATE; INTERLEUKIN 6; NESIRITIDE; NEUROHORMONE; PLACEBO; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART FAILURE; ANTIINFLAMMATORY ACTIVITY; BOLUS INJECTION; BRONCHODILATATION; CANADA; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE INCREASE; DRUG MECHANISM; DYSPNEA; FORCED EXPIRATORY VOLUME; GLOMERULUS FILTRATION RATE; HEART AFTERLOAD; HEART OUTPUT; HEART PRELOAD; HORMONE INHIBITION; HOSPITAL PATIENT; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; MOLECULAR WEIGHT; NATRIURESIS; NONHUMAN; PULMONARY ARTERY OCCLUSION PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR RESISTANCE; VASODILATATION;

EID: 48749100491     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0828-282x(08)71024-9     Document Type: Review

References (28)

1. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi Jr JL. Biology of the natriuretic peptides. Am J Cardiol 2008;101(Suppl A):3A-8A.
2. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071-8.
3. Agency for Healthcare Research and Quality. Testing for BNP and NT-proBNP in the Diagnosis and Prognosis of Heart Failure. Evidence report#142, September 2006. (Version current at May 20, 2008).
4. Lam CS, Burnett Jr. JCB, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 2007;49:1193-202.
5. Worster A, Balion CM, Hill SA, et al. Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: A systematic review. Clin Biochem 2008;41:250-9.
6. Hawkridge AM, Heublein DM, Bergen HR 3rd, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 2005;102:17442-47.
7. Pandey KN. Biology of natriuretic peptides and their receptors. Peptides 2005;26:901-32.
8. Chen HH. Heart failure: A state of brain natriuretic peptide deficiency or resistance or both! J Am Coll Cardiol 2007;49(10):1089-91.
9. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357-68.
10. Houben AJHM, van der Zander K, de Leeuw PW. Vascular and renal actions of brain natriuretic peptide in man: Physiology and pharmacology. Fundam Clin Pharmacol 2005;19:411-19.
11. Protter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens 1996;9:432-36.
12. Schmitt M, Gunaruwan P, Payne N, et al. Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure. Arterioscler Thromb Vasc Biol 2004;24:911-17.
13. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000;343:246-53.
14. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002;287:1531-40. (Erratum in JAMA 2002;288:577).
15. Zellner C, Protter AA, Ko E, et al. Coronary vasodilator effects of BNP: Mechanisms of action in coronary conductance and resistance arteries. Am J Physiol 1999;276(3 Pt 2):H1049-57.
16. Michaels AD, Klein A, Madden JA, Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003;107:2697-701.
17. Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Can J Cardiol 2006;22:22-45. (Erratum in 2006;22:271).
18. Libby P, Bonow RO, Mann DL. Braunwald's Heart Disease. Toronto: Elsevier Health Sciences, 2007.
19. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44.
20. Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med 2002;3(Suppl 4):S18-27.
21. Burger AJ. A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest Heart Fail 2005;11:30-8.
22. Heywood JT. The cardiorenal syndrome: Lessons from the ADHERE database and treatment options. Heart Fail Rev 2004;9:195-201.
23. Boerrigter G, Burnett JC Jr. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs 2004;13:643-52.
24. Mentzer RM, Oz MC, Sladen RN, et al; NAPA Investigators. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: The NAPA trial. J Am Coll Cardiol 2007;49:716-26.
25. Marcus LS, Hart D, Packer M, et al. Myocardial disease: Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184-9.
26. Akerman MJ, Yaegashi M, Khiangte Z, Murugan AT, Abe O, Marmur JD. Bronchodilator effect of infused B-type natriuretic peptide in asthma. Chest 2006;130:66-72.
27. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000;97:4239-44.
28. Kapoun AM, Liang F, O'Young G, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004;94:453-61.